Featured Research

from universities, journals, and other organizations

Raloxifene After Tamoxifen Not Beneficial, According To New Study

Date:
February 20, 2002
Source:
Northwestern University
Summary:
Taking raloxifene after five years of tamoxifen therapy does not prevent the recurrence of breast cancer in postmenopausal women and may actually stimulate growth of endometrial tumors, according to a Northwestern University study.

Taking raloxifene after five years of tamoxifen therapy does not prevent the recurrence of breast cancer in postmenopausal women and may actually stimulate growth of endometrial tumors, according to a Northwestern University study.

Related Articles


As described in an article in the Feb. 20 issue of the Journal of the National Cancer Institute, researchers Ruth M. O’Regan, M.D.,V. Craig Jordan and colleagues at Northwestern evaluated the effects on tumor growth of raloxifene after tamoxifen treatment in mouse models of breast and endometrial cancers.

They found that, after exposing breast and endometrial tumors in mice to combinations of estrogen, tamoxifen, raloxifene or no drug at all, raloxifene did not further prevent growth of breast tumors previously exposed to more than five years of tamoxifen. Moreover, raloxifene was less effective than tamoxifen in blocking the growth of endometrial tumors caused by low-dose estrogen.

Tamoxifen is a selective estrogen receptor modulator (SERM) that reduces breast cancer recurrence in women with early-stage breast cancer. However, studies show that the benefits of tamoxifen diminish after five years and that additional therapy with tamoxifen may significantly increase a woman’s risk for endometrial cancer.

Some studies have suggested that SERM raloxifene, which is used to prevent osteoporosis in postmenopausal women, may decrease risk for breast cancer without increasing risk for endometrial cancer.

Based on the results of their study, the Northwestern researchers now believe that in women completing five years of tamoxifen therapy, raloxifene may not further reduce the risk for breast cancer recurrence.

However, the ongoing Study of Tamoxifen and Raloxifene (STAR) study, a large randomized clinical trial that is comparing the effects of raloxifene and tamoxifen on the primary prevention of breast cancer and endometrial cancer in high-risk women, may provide more definitive answers on the utility of raloxifene following tamoxifen therapy.

O’Regan is an instructor in medicine at Northwestern University Medical School. Jordan is the Diana, Princess of Wales, Professor of Cancer Research; professor molecular pharmacology and biological chemistry at the Medical School; and director of Lynn Sage Breast Cancer Research Program at The Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Co-authors on the article include Cancer Center researchers Csaba Gajdos, Alex De Los Reyes, Woochan Park and Alfred W. Rademaker. Rita C. Dardes is affiliated with the Federal University of Sao Paulo, Brazil.


Story Source:

The above story is based on materials provided by Northwestern University. Note: Materials may be edited for content and length.


Cite This Page:

Northwestern University. "Raloxifene After Tamoxifen Not Beneficial, According To New Study." ScienceDaily. ScienceDaily, 20 February 2002. <www.sciencedaily.com/releases/2002/02/020220075200.htm>.
Northwestern University. (2002, February 20). Raloxifene After Tamoxifen Not Beneficial, According To New Study. ScienceDaily. Retrieved March 2, 2015 from www.sciencedaily.com/releases/2002/02/020220075200.htm
Northwestern University. "Raloxifene After Tamoxifen Not Beneficial, According To New Study." ScienceDaily. www.sciencedaily.com/releases/2002/02/020220075200.htm (accessed March 2, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, March 2, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Treadmill Test Can Predict Chance Of Death Within A Decade

Treadmill Test Can Predict Chance Of Death Within A Decade

Newsy (Mar. 2, 2015) Johns Hopkins researchers analyzed 58,000 heart stress tests to come up with a formula that predicts a person&apos;s chances of dying in the next decade. Video provided by Newsy
Powered by NewsLook.com
Going Gluten-Free Could Get You A Tax Break

Going Gluten-Free Could Get You A Tax Break

Newsy (Mar. 2, 2015) If a doctor advises you to remove gluten from your diet, you could get a tax deduction on the amount you spend on gluten-free foods. Video provided by Newsy
Powered by NewsLook.com
GlaxoSmithKline and Novartis Try Swapping Success

GlaxoSmithKline and Novartis Try Swapping Success

Reuters - Business Video Online (Mar. 2, 2015) GlaxoSmithKline and Novartis have completed a series of asset swaps worth more than $20 billion. As Grace Pascoe reports they say the deal will reshape both drugmakers. Video provided by Reuters
Powered by NewsLook.com
How Can West Africa Rebuild After Ebola?

How Can West Africa Rebuild After Ebola?

Reuters - Business Video Online (Mar. 2, 2015) How best to rebuild the three West African countries struggling with Ebola will be discussed in Brussels this week. As Hayley Platt reports Sierra Leone has the toughest job ahead - its once thriving economy has been ravaged by the disease. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins